Milton Packer

118.2k total citations · 38 hit papers
655 papers, 65.6k citations indexed

About

Milton Packer is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Milton Packer has authored 655 papers receiving a total of 65.6k indexed citations (citations by other indexed papers that have themselves been cited), including 515 papers in Cardiology and Cardiovascular Medicine, 163 papers in Endocrinology, Diabetes and Metabolism and 120 papers in Surgery. Recurrent topics in Milton Packer's work include Heart Failure Treatment and Management (370 papers), Cardiovascular Function and Risk Factors (216 papers) and Diabetes Treatment and Management (144 papers). Milton Packer is often cited by papers focused on Heart Failure Treatment and Management (370 papers), Cardiovascular Function and Risk Factors (216 papers) and Diabetes Treatment and Management (144 papers). Milton Packer collaborates with scholars based in United States, United Kingdom and Canada. Milton Packer's co-authors include Jean L. Rouleau, John J.V. McMurray, Scott D. Solomon, Michael R. Zile, Karl Swedberg, Victor Shi, Michael B. Fowler, Martin Lefkowitz, Akshay S. Desai and Wilson S. Colucci and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Milton Packer

641 papers receiving 63.0k citations

Hit Papers

Effect of Captopril on Mo... 1986 2026 1999 2012 1992 2014 1996 2002 2001 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction
    1992 4.4k citations Marc A. Pfeffer, Milton Packer et al. profile →
  2. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
    2014 4.3k citations John J.V. McMurray, Milton Packer et al. profile →
  3. The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
    1996 3.4k citations Milton Packer et al. profile →
  4. Cardiac Resynchronization in Chronic Heart Failure
    2002 3.3k citations William T. Abraham, Milton Packer et al. profile →
  5. Effect of Carvedilol on Survival in Severe Chronic Heart Failure
    2001 2.2k citations Milton Packer, Jean L. Rouleau et al. profile →
  6. Elevated Circulating Levels of Tumor Necrosis Factor in Severe Chronic Heart Failure
    1990 2.1k citations Milton Packer et al. profile →
  7. Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure
    1991 1.6k citations Milton Packer et al. profile →
  8. The Seattle Heart Failure Model
    2006 1.5k citations Stefan D. Anker, Inder S. Anand et al. Circulation profile →
  9. Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart Failure
    2003 1.3k citations Milton Packer et al. Circulation profile →
  10. Targeted Anticytokine Therapy in Patients With Chronic Heart Failure
    2004 955 citations John J.V. McMurray, Milton Packer et al. Circulation profile →
  11. Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure
    2002 928 citations Milton Packer, Jean L. Rouleau et al. Circulation profile →
  12. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
    2012 883 citations Scott D. Solomon, Michael R. Zile et al. profile →
  13. Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure
    1999 833 citations Milton Packer, John G.F. Cleland et al. Circulation profile →
  14. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
    2020 831 citations Faı̈ez Zannad, João Pedro Ferreira et al. profile →
  15. Effect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart Failure
    1996 808 citations Milton Packer et al. profile →
  16. Sex Differences in the Management of Coronary Artery Disease
    1991 731 citations Milton Packer, Marc A. Pfeffer et al. profile →
  17. Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure
    2007 645 citations Milton Packer, Stuart Pocock et al. profile →
  18. Withdrawal of Digoxin from Patients with Chronic Heart Failure Treated with Angiotensin-Converting-Enzyme Inhibitors
    1993 553 citations Milton Packer et al. profile →
  19. Impaired Systolic Function by Strain Imaging in Heart Failure With Preserved Ejection Fraction
    2013 527 citations Elisabeth Kraigher‐Krainer, Amil M. Shah et al. Journal of the American College of Cardiology profile →
  20. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure.
    1986 431 citations Milton Packer et al. Circulation profile →
  21. Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium
    2018 425 citations Milton Packer Journal of the American College of Cardiology profile →
  22. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials
    2020 362 citations Muthiah Vaduganathan, Brian Claggett et al. profile →
  23. Proportionate and Disproportionate Functional Mitral Regurgitation
    2018 345 citations Milton Packer et al. profile →
  24. Dual Angiotensin Receptor and Neprilysin Inhibition as an Alternative to Angiotensin-Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure: Rationale for and Design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure Trial (PARADIGM-HF)
    2013 339 citations John J.V. McMurray, Milton Packer et al. European Journal of Heart Failure profile →
  25. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients
    2015 302 citations Akshay S. Desai, John J.V. McMurray et al. European Heart Journal profile →
  26. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure
    2018 291 citations Mauro Gori, Brian Claggett et al. JACC Heart Failure profile →
  27. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
    2024 284 citations Milton Packer, Michael R. Zile et al. profile →
  28. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure
    2017 269 citations Milton Packer, Stefan D. Anker et al. profile →
  29. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction
    2020 266 citations Milton Packer, Stefan D. Anker et al. Circulation profile →
  30. Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis
    2022 255 citations Milton Packer Circulation profile →
  31. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status
    2020 243 citations Stefan D. Anker, Javed Butler et al. Circulation profile →
  32. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial
    2021 226 citations Milton Packer, Javed Butler et al. Circulation profile →
  33. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction
    2021 159 citations Javed Butler, Milton Packer et al. European Heart Journal profile →
  34. Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox
    2023 129 citations Jawad H. Butt, Pardeep S. Jhund et al. European Heart Journal profile →
  35. SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism
    2023 107 citations Milton Packer profile →
  36. Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure
    2024 63 citations Christopher M. Kramer, Barry A. Borlaug et al. Journal of the American College of Cardiology profile →
  37. Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial
    2024 46 citations Barry A. Borlaug, Michael R. Zile et al. Nature Medicine profile →
  38. Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial
    2025 35 citations Muthiah Vaduganathan, Brian Claggett et al. European Heart Journal profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Milton Packer 52.9k 10.6k 9.4k 8.5k 7.3k 655 65.6k
Karl Swedberg 53.2k 1.0× 9.6k 0.9× 5.9k 0.6× 8.7k 1.0× 4.1k 0.6× 507 64.0k
Faı̈ez Zannad 38.6k 0.7× 19.2k 1.8× 10.2k 1.1× 11.6k 1.4× 7.7k 1.1× 958 57.7k
Dirk J. van Veldhuisen 43.8k 0.8× 5.6k 0.5× 7.9k 0.8× 7.7k 0.9× 5.7k 0.8× 857 60.8k
Gerasimos Filippatos 30.8k 0.6× 7.9k 0.7× 6.3k 0.7× 7.5k 0.9× 5.0k 0.7× 625 43.8k
Lars Køber 39.2k 0.7× 10.1k 1.0× 10.5k 1.1× 5.6k 0.7× 6.0k 0.8× 1.4k 59.4k
Javed Butler 29.1k 0.5× 8.1k 0.8× 6.4k 0.7× 6.2k 0.7× 4.5k 0.6× 825 42.1k
Aldo P. Maggioni 35.8k 0.7× 9.5k 0.9× 8.0k 0.9× 5.4k 0.6× 4.3k 0.6× 873 49.2k
Giuseppe Mancia 46.3k 0.9× 11.8k 1.1× 10.8k 1.2× 4.2k 0.5× 2.8k 0.4× 1.3k 63.5k
Bertram Pitt 32.5k 0.6× 12.0k 1.1× 9.0k 1.0× 8.7k 1.0× 4.3k 0.6× 578 45.8k
Adriaan A. Voors 28.3k 0.5× 5.7k 0.5× 5.6k 0.6× 7.2k 0.8× 5.1k 0.7× 688 41.4k

Countries citing papers authored by Milton Packer

Since Specialization
Citations

This map shows the geographic impact of Milton Packer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Milton Packer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Milton Packer more than expected).

Fields of papers citing papers by Milton Packer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Milton Packer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Milton Packer. The network helps show where Milton Packer may publish in the future.

Co-authorship network of co-authors of Milton Packer

This figure shows the co-authorship network connecting the top 25 collaborators of Milton Packer. A scholar is included among the top collaborators of Milton Packer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Milton Packer. Milton Packer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Matsumoto, Shingo, Jawad H. Butt, Kieran F. Docherty, et al.. (2025). Obesity, aldosterone, and natriuretic peptides in patients with heart failure and reduced ejection fraction. Cardiovascular Research. 122(1). 14–18.
2.
Ferreira, João Pedro, Pedro Marques, Stefan D. Anker, et al.. (2025). Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials. Diabetes Obesity and Metabolism. 28(2). 1105–1115.
3.
Kondo, Toru, Pardeep S. Jhund, Inder S. Anand, et al.. (2025). Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF. JACC Heart Failure. 13(6). 927–939. 2 indexed citations
4.
Siddiqi, Tariq Jamal, Milton Packer, Justin A. Ezekowitz, et al.. (2025). Diuretic Potentiation Strategies in Acute Heart Failure. JACC Heart Failure. 13(1). 14–27. 1 indexed citations
5.
Sattar, Naveed, Javed Butler, Matthew M.Y. Lee, et al.. (2024). Body Mass Index and Cardiorenal Outcomes in the EMPEROR-Preserved Trial: Principal Findings and Meta-Analysis with the DELIVER Trial. European Journal of Heart Failure. 26(4). 900–909. 15 indexed citations
6.
Borlaug, Barry A., Michael R. Zile, Christopher M. Kramer, et al.. (2024). Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nature Medicine. 31(2). 544–551. 46 indexed citations breakdown →
7.
Packer, Milton. (2024). Traditional Chinese medicine: cardiovascular drug development through a holistic framework. European Heart Journal. 45(40). 4315–4317. 1 indexed citations
8.
Talha, Khawaja M., Jennifer Green, Gerasimos Filippatos, et al.. (2024). Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR‐Pooled analysis. Diabetes Obesity and Metabolism. 26(7). 2578–2587. 3 indexed citations
9.
Ferreira, João Pedro, Javed Butler, Bettina J. Kraus, et al.. (2024). Early Changes in Estimated Glomerular Filtration Rate Post-Initiation of Empagliflozin in EMPEROR-Preserved. European Journal of Heart Failure. 26(4). 885–896. 10 indexed citations
10.
Chatur, Safia, Iris E. Beldhuis, Brian Claggett, et al.. (2024). Sacubitril/Valsartan in Patients With Heart Failure and Deterioration in eGFR to <30 mL/min/1.73 m2. JACC Heart Failure. 12(10). 1692–1703. 5 indexed citations
11.
Lu, Henri, Brian Claggett, Milton Packer, et al.. (2024). Race in Heart Failure. JACC Heart Failure. 13(1). 58–71.
12.
Foà, Alberto, Muthiah Vaduganathan, Brian Claggett, et al.. (2024). Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction. Journal of the American College of Cardiology. 83(18). 1731–1739. 3 indexed citations
13.
Packer, Milton, Stefan D. Anker, Javed Butler, et al.. (2024). Redefining Iron Deficiency in Patients With Chronic Heart Failure. Circulation. 150(2). 151–161. 19 indexed citations
14.
Packer, Milton, Stefan D. Anker, Javed Butler, et al.. (2024). Identification of three mechanistic pathways for iron-deficient heart failure. European Heart Journal. 45(26). 2281–2293. 13 indexed citations
15.
Ferreira, João Pedro, Francisca Saraiva, Abhinav Sharma, et al.. (2023). Glucagon‐like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta‐analysis of randomized placebo‐controlled outcome trials. Diabetes Obesity and Metabolism. 25(6). 1495–1502. 39 indexed citations
16.
Ferreira, João Pedro, Milton Packer, Javed Butler, et al.. (2023). Growth Differentiation Factor-15 and the Effect of Empagliflozin in Heart Failure: Findings from the EMPEROR Program. European Journal of Heart Failure. 26(1). 155–164. 11 indexed citations
17.
Yang, Mingming, Toru Kondo, Carly Adamson, et al.. (2023). Knowledge About Self-Efficacy and Outcomes in Patients with Heart Failure and Reduced Ejection Fraction. European Journal of Heart Failure. 25(10). 1831–1839. 3 indexed citations
18.
Zannad, Faı̈ez, João Pedro Ferreira, Stuart Pocock, et al.. (2020). Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function. Circulation. 143(4). 310–321. 180 indexed citations
19.
Gori, Mauro, Carolyn S.P. Lam, Deepak K. Gupta, et al.. (2014). Sex-Specific Cardiovascular Structure and Function in Heart Failure with Preserved Ejection Fraction. European Journal of Heart Failure. 16(5). 535–542. 178 indexed citations
20.
McMurray, John J.V., Milton Packer, Akshay S. Desai, et al.. (2013). Dual Angiotensin Receptor and Neprilysin Inhibition as an Alternative to Angiotensin-Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure: Rationale for and Design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure Trial (PARADIGM-HF). European Journal of Heart Failure. 15(9). 1062–1073. 339 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karl Swedberg Breakdown of academic impact, for papers by Faı̈ez Zannad Breakdown of academic impact, for papers by Dirk J. van Veldhuisen Breakdown of academic impact, for papers by Gerasimos Filippatos Breakdown of academic impact, for papers by Lars Køber Breakdown of academic impact, for papers by Javed Butler Breakdown of academic impact, for papers by Aldo P. Maggioni Breakdown of academic impact, for papers by Giuseppe Mancia Breakdown of academic impact, for papers by Bertram Pitt Breakdown of academic impact, for papers by Adriaan A. Voors
Rankless by CCL
2026